Lower risk of CV Events or deaths in prostate cancer patients treated with degarelix compared to LHRH agonists
The gonadotropin releasing hormone (GnRH) antagonist degarelix (brand name Firmagon, from Swiss drugmaker Ferring Pharmaceuticals) may be associated with lower risk of a cardiovascular (CV) events or death compared to commonly prescribed luteinizing hormone-releasing hormone (LHRH) agonists, according to data presented at the European Association of Urology (EAU) 2013 annual meeting in Milan, Italy.
These data are based on a pooled analysis of 2,328 men with prostate cancer from six prospective, randomized trials. Analysis of the data also revealed that the men in the studies treated with Firmagon had significantly higher overall survival and improved disease control as evidenced by fewer fractures and a lower incidence of renal or urinary tract adverse events compared to men treated with LHRH agonists.
Less risk of CV events or deaths
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze